CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Tigecyclinedrug
Likely dose
Tigecycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01560143
NCT01560143Phase 4Completed
CompareCT.gov

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

Manjunath Prakash Pai·interventional·Posted Mar 22, 2012·Updated Feb 9, 2017

In Brief

A Phase 4 clinical trial evaluating Tigecycline for Obesity. Completed, enrolled 12 participants across 1 site.

Detailed Summary

If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without regard to weight.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 22, 2012
Enrollment StartMar 1, 2012
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.3 years ago

Interventions

Tigecyclinedrug

100 mg IV as a single infusion over 30 minutes